Tom 14, Nr 2 (2017)
Zaburzenia rytmu serca
Opublikowany online: 2017-08-24

dostęp otwarty

Wyświetlenia strony 675
Wyświetlenia/pobrania artykułu 26686
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Zaburzenia rytmu serca u kobiet

Andrzej J. Sałacki, Andrzej Wysokiński
Choroby Serca i Naczyń 2017;14(2):66-74.

Streszczenie

Odmienności nadkomorowych i komorowych zabu­rzeń rytmu serca u kobiet i mężczyzn są od dawna powszechnie znane. Obserwacje kliniczne pozwoliły wyciągnąć wnioski o przewadze występowania nie­których ich rodzajów u kobiet. Wynika to z zależnych od płci różnic w parametrach elektrofizjologicznych, których przyczyny nie są dokładnie poznane. Upatruje się je we właściwościach samego węzła zatokowego, w różnej spoczynkowej czynności serca, ekspresji i w rozmieszczeniu podjednostek kanałów jonowych w sercu, a także we wpływie hormonów płciowych u kobiet. Różnice te powodują odmienności w zależ­ności od płci w częstości występowania arytmii, jej przebiegu klinicznym, odpowiedzi na leczenie oraz rokowaniu. Dotyczy to zarówno nadkomorowych, jak i komorowych zaburzeń rytmu serca. Zaburzenia ryt­mu i przewodzenia u kobiet częściej występują pod postacią choroby węzła zatokowego w porównaniu z zaburzeniami przewodnictwa przedsionkowo-ko­morowego, które przeważają u mężczyzn. W pracy zwrócono uwagę na zaburzenia rytmu częściej wystę­pujące u kobiet, szukano odpowiedzi, dlaczego tak się dzieje, a także jak to wpływa na rokowanie odległe.

Referencje

  1. Burke JH, Goldberger JJ, Ehlert FA, et al. Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Am J Med. 1996; 100(5): 537–543.
  2. Taneja T, Mahnert BW, Passman R, et al. Effects of sex and age on electrocardiographic and cardiac electrophysiological properties in adults. Pacing Clin Electrophysiol. 2001; 24(1): 16–21.
  3. Volkmann H, Schnerch B, Kühnert H. Diagnostic value of carotid sinus hypersensitivity. Pacing Clin Electrophysiol. 1990; 13(12 Pt 2): 2065–2070.
  4. Albert CM, Ruskin JN. Arrhythmias and the use of implantable cardioverter-defibrillator. In: Julina DG, Wenger NK. ed. Women and heart disease. Mosby, Martin Dunitz, London 1997: 363–373.
  5. Ghani A, Maas AH, Delnoy PP, et al. Sex-based differences in cardiac arrhythmias, ICD utilisation and cardiac resynchronisation therapy. Neth Heart J. 2011; 19(1): 35–40.
  6. Insulander P, Vallin H. Arrythmias. In: Schenck-Gustatafsson K, DeCola PR, Pfaff DW, Pisetsky DS. ed. Handbook of clinical gender medicine. Karger, Basel 2012: 229–236.
  7. Deneke T, Müller P, Lawo T, et al. Gender differences in onset of symptoms in AV nodal re-entrant and accessory pathway-mediated re-entrant tachycardia. Herzschrittmacherther Elektrophysiol. 2009; 20(1): 33–38.
  8. Janion M, Janion-Sadowska A. Nadkomorowe i komorowe zaburzenia rytmu — skala problemu u kobiet. Przegl Lek. 2014; 71(3): 142–146.
  9. Świątecka G, Kornacewicz-Jach Z. Zaburzenia rytmu serca. In: Świątecka G. ed. Choroby serca u kobiet. Via Medica, Gdańsk 2007: 503–523.
  10. Biernacka EK. Genetycznie uwarunkowane zaburzenia rytmu serca a płeć. Przegl Lek. 2014; 71(3): 139–141.
  11. Gowd BM, Thompson PD. Effect of female sex on cardiac arrhythmias. Cardiol Rev. 2012; 20(6): 297–303.
  12. Moric-Janiszewska E, Głogowska-Ligus J, Paul-Samojedny M, et al. Age-and sex-dependent mRNA expression of KCNQ1 and HERG in patients with long QT syndrome type 1 and 2. Arch Med Sci. 2011; 7(6): 941–947.
  13. Jiang C, Poole-Wilson PA, Sarrel PM, et al. Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 1992; 106(3): 739–745.
  14. Eckstein N, Nadler E, Barnea O, et al. Acute effects of 17 beta-estradiol on the rat heart. Am J Obstet Gynecol. 1994; 171(3): 844–848.
  15. Raddino R, Manca C, Poli E, et al. Effects of 17 beta-estradiol on the isolated rabbit heart. Arch Int Pharmacodyn Ther. 1986; 281(1): 57–65.
  16. Marni F, Wang Y, Morishima M, et al. 17 beta-estradiol modulates expression of low-voltage-activated Ca(V)3.2 T-type calcium channel via extracellularly regulated kinase pathway in cardiomyocytes. Endocrinology. 2009; 150(2): 879–888.
  17. Rodriguez LM, de Chillou C, Schläpfer J, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol. 1992; 70(13): 1213–1215.
  18. Di Fusco SA, Palazzo S, Colivicchi F, et al. World Society of Arrhythmias. The influence of gender on heart rhythm disease. Pacing Clin Electrophysiol. 2014; 37(5): 650–657.
  19. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013; 274(5): 461–468.
  20. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013; 15(4): 486–493.
  21. Zoni-Berisso M, Filippi A, Landolina M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol. 2013; 111(5): 705–711.
  22. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 2012; 5(1): 85–93.
  23. Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011; 13(8): 1110–1117.
  24. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013; 99(16): 1166–1172.
  25. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129(8): 837–847.
  26. Gómez-Doblas JJ, Muñiz J, Martin JJ, et al. OFRECE study collaborators. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol (Engl Ed). 2014; 67(4): 259–269.
  27. Sałacki AJ, Wysokiński A. Pacjent z migotaniem przedsionków w praktyce lekarza rodzinnego. Forum Med Rodz. 2016; 10(3): 111–118.
  28. Shen WK. Modification and ablation for inappropriate sinus tachycardia: current status. Card Electrophysiol Rev. 2002; 6(4): 349–355.
  29. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias — executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE — Heart Rhythm Society. J Am Coll Cardiol. 2003; 42(8): 1493–1531.
  30. Głuszak A, Kocoń S, Zuk K, et al. Episodes of atrial fibrillation and meteorological conditions. Kardiol Pol. 2008; 66(9): 958–63; discussion 964.
  31. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003; 108(6): 711–716.
  32. Go AS, Hylek EM, Philips KA. Prevalence of diagnosed atrial fibrillation in adults: national implication for rhythm management and stroke prevention. The AnTicoagulation and Risk factors in Atrial fibrillation (ATRIA) study. JAMA. 2001; 285: 2370–2375.
  33. Eurostat methodologies and working papers. Work session on demographic progressions. Lisbon, Portugal, April 28–30, 2010.
  34. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007; 93(5): 606–612.
  35. Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213–220.
  36. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11(4): 423–434.
  37. Di Pasquale G, Mathieu G, Maggioni AP, et al. ATA-AF Investigators. Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. Int J Cardiol. 2013; 167(6): 2895–2903.
  38. Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation. 1999; 99(23): 3028–3035.
  39. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271(11): 840–844.
  40. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005; 112(12): 1687–1691.
  41. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial Fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19): 2369–2429.
  42. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG, Document Reviewers, ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21): 2719–2747.
  43. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. RACE Investigators. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2005; 46(7): 1298–1306.
  44. Friberg J, Scharling H, Gadsbøll N, et al. Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004; 94(7): 889–894.
  45. Rosano GM, Leonardo F, Sarrel PM, et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996; 347(9004): 786–788.
  46. Myerburg R, Cox M, Interian A, et al. Cycling of inducibility of paroxysmal supraventricular tachycardia in women and its implications for timing of electrophysiologic procedures. Am J Cardiol. 1999; 83(7): 1049–1054.
  47. Tada H, Oral H, Greenstein R, et al. Analysis of age of onset of accessory pathway-mediated tachycardia in men and women. Am J Cardiol. 2002; 89(4): 470–471.
  48. Narasimha D, Curtis AB, Curtis AB, et al. Arrhythmias in women. Clin Cardiol. 2012; 35(3): 166–171.
  49. Burger AJ, Aronson D. Age and sex as determinants of ventricular arrhythmic events in patients with decompensated congestive heart failure. Ann Noninvasive Electrocardiol. 2002; 7(3): 234–241.
  50. Burger AJ, Horton DP, LeJemtel T. . Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002 Dec;144(6):1102-8. 2002; 144(6): 1102–1108.
  51. Marchlinski FE, Deely MP, Zado ES. Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J. 2000; 139(6): 1009–1013.
  52. Kannel WB, Wilson PW, D'Agostino RB, et al. Sudden coronary death in women. Am Heart J. 1998; 136(2): 205–212.
  53. Wigginton JG, Pepe PE, Bedolla JP, et al. Sex-related differences in the presentation and outcome of out-of-hospital cardiopulmonary arrest: a multiyear, prospective, population-based study. Crit Care Med. 2002; 30(4 Suppl): S131–S136.
  54. Simmons A, Pimentel R, Lakkireddy D. Sudden cardiac death in women. Rev Cardiovasc Med. 2012; 13(1): e37–e42.
  55. Myerburg RJ. Epidemiology of ventricular tachycardia/ventricular fibrillation and sudden cardiac death. Pacing Clin Electrophysiol. 1986; 9(6): 1334–1338.
  56. Kulbertus H. [Cardiac arrhythmias in women]. Rev Med Liege. 1999; 54(4): 251–254.
  57. Deo R, Vittinghoff E, Lin F, et al. Risk factor and prediction modeling for sudden cardiac death in women with coronary artery disease. Arch Intern Med. 2011; 171(19): 1703–1709.
  58. Hashiba K. Hereditary QT prolongation syndrome in Japan: genetic analysis and pathological findings of the conducting system. Jpn Circ J. 1978; 42(10): 1133–1150.
  59. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998; 97(22): 2237–2244.
  60. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998; 97(22): 2237–2244.
  61. Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. Curr Probl Cardiol. 2008; 33(11): 629–694.
  62. Ferrer MI. The sick sinus syndrome in atrial disease. JAMA. 1968; 206(3): 645–646.
  63. Adán V, Crown LA. Diagnosis and treatment of sick sinus syndrome. Am Fam Physician. 2003; 67(8): 1725–1732.
  64. Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med. 2000; 342(10): 703–709.
  65. Peregud-Pogorzelska M, Kornacewicz-Jach Z. Choroba węzła zatokowego, zaburzenia przewodzenia przedsionkowo-komorowego u kobiet- częstość występowania, postępowanie. Przegl Lek. 2014; 71(3): 169–171.
  66. Roman JS, Medina CO, Hernandez JG, et al. Complete auriculoventricular blockage in adult patients with systemic lupus erythematosus. Case series and review of the literature. Reumatol Clin. 2006; 2: 294–297.
  67. Femenía F, Arce M, Arrieta M. [Systemic sclerosis complicated with syncope and complete AV block]. Medicina (B Aires). 2010; 70(5): 442–444.
  68. Alboni P, Menozzi C, Brignole M, et al. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the THEOPACE study: a randomized controlled trial. Circulation. 1997; 96(1): 260–266.
  69. Kristensen L, Nielsen JC, Pedersen AK, et al. AV block and changes in pacing mode during long-term follow-up of 399 consecutive patients with sick sinus syndrome treated with an AAI/AAIR pacemaker. Pacing Clin Electrophysiol. 2001; 24(3): 358–365.
  70. Wytyczne ESC dotyczące stymulacji serca i terapii resynchronizującej w 2013 roku. Kardiol Pol. 2013; 71(Suppl V): 133–192.